Patient P-01339
Therapy response 44 at the day-84 endpoint (observed).
Responding: response probability 47%, therapy response 48 today; biology is not blocking the drug.
Drift detected on day 46 (HRV −7 ms, resting HR +4 bpm, gi toxicity +16, inflammatory load +14); the side effect would have been reported on day 50 — 4 days of warning.
6 of 9 scheduled doses in the last 60 days are biologically confirmed (67%); 1 were logged but show no dose signature. Dose signature: resting HR +7 bpm, HRV −9 ms.
77% of 284 similar trajectories improved after NP-02; if this one does, discontinuation risk is expected to fall from 96% to ~77%. Keeping histamine low is worth 6.2 GI points a day on its own. Losing this patient costs €57k; the intervention costs €180.
- 🍽Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- 🍽Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- ✓Track each bowel movement today: time, stool form, urgency, overnight waking
- ✓A 15-minute walk after lunch
- 💊Take the scheduled dose as agreed with your care team
- 💊Electrolyte solution, one sachet after any loose stool
Dose is being missed; nothing else works until this is fixed.
GI burden above 80 for 3 days within the onset window
P-01339 is on day 117 of NBL-101 (EC-03, baseline S14): response improving, tolerance improving, GI unstable. Over 14 days response moved +11 and GI +20; discontinuation risk is 96%. The state is between basins, heading towards failing, after diverging from the model on day 46.
Biology sets the gain: FUT2 non-secretor, IL6 high-expression variant, Low butyrate capacity, Low microbial diversity, Baseline state S14, Cluster EC-03 (high response / high intolerance), Adherence < 60%; butyrate capacity 27/100, diversity 2.0. Pushing it down: Escherichia coli 31.089% (LPS load) (-36.3), Low butyrate capacity (-28.5), Histamine load (-22.5). Pulling it up: GI Support Protocol GI-04 (+31.2). From the daily log: histamine +6.2 GI next day, fat +6 GI next day, simple carbs +5.8 GI next day, spicy +5.6 GI next day.
Past actions: GI-04 on day 60 → improved (19%).
Next: NP-02 — 77% of 284 similar trajectories improved, 67% probability here. This would be contradicted by a further GI rise within the onset window or falling adherence.
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and events- Day 0 NBL-101 started — Baseline state S14
- Day 46 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 59 GI-04 recommended — GI Support Protocol GI-04
- Day 60 Patient accepted — Started GI-04 in the companion
- Day 68 GI symptom burden −19% vs expected — GI Support Protocol GI-04
- Day 74 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 46.
- GI instability+20
- Nutritional resilience-10
- Toxicity-7
- Inflammatory activity+2
What helped?
- GI Support Protocol GI-04Day 59Result: symptom burden −19%
- 284 similar trajectories
- 77% showed improvement
- median effect visible after 10 days
Daily trackers
Asset settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Heading towards failing · 28 from the failing basin, 71 from restoration.
- Keep histamine lowGI +6.2 next day on high-intake days · n 20
- Keep fat lowGI +6 next day on high-intake days · n 22
- Keep simple carbs lowGI +5.8 next day on high-intake days · n 17
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Histamine load+6.2detractor · 95%
- Dietary fat load+6detractor · 95%
- Simple carbohydrates+5.8detractor · 95%
- Spicy / capsaicin+5.6detractor · 95%
- Alcohol-2.5no signal · 41%
- Insoluble fibre0no signal · 15%
DeepGene damage signature
The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.
- 5 opportunists above range: Escherichia coli, Klebsiella pneumoniae, Enterococcus faecium
- 6 keystone species absent
- Shannon 2.05 (expected ≥ 3)
- 11 resistance genes
- Tissue recycling index 55
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 72 and rising
- WearableSleep 5.8 h, below personal baseline
- Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 57
- WearableHRV 31 ms, trending down
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 27/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓65
- WearableResting HR 89 bpm
- Wearable511 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 45
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
- HRV
- 35 ms
- Sleep
- 5.5 h
- Steps
- 526
- Resting HR
- 86 bpm
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01345 | 20% | S02 | AD-05 | improved | 36 |
| P-01650 | 21% | S14 | BR-03 | improved | 38 |
| P-01540 | 20% | S14 | BR-03 | improved | 32 |
| P-01600 | 35% | S09 | CR-01 | improved | 58 |
| P-01768 | 35% | S17 | CR-01 | improved | 58 |
| P-01877 | 30% | S01 | CR-01 | improved | 61 |
| P-01514 | 29% | S13 | CR-01 | improved | 46 |
| P-01708 | 29% | S14 | CR-01 | improved | 63 |
| P-01699 | 28% | S19 | CR-01 | improved | 55 |
| P-01697 | 24% | S13 | CR-01 | improved | 56 |
| P-01725 | 23% | S01 | CR-01 | improved | 62 |
| P-01794 | 22% | S13 | CR-01 | improved | 51 |